| 书目名称 | New Therapeutic Targets in Rheumatoid Arthritis |
| 编辑 | Paul-Peter Tak |
| 视频video | |
| 概述 | Focuses on therapeutic targets that have recently been registered or are currently under development..Each chapter discusses the biological rationale in great detail including results from clinical tr |
| 丛书名称 | Progress in Inflammation Research |
| 图书封面 |  |
| 描述 | During the past decades important breakthroughs have been made in the treatment of rheumatoid arthritis (RA). First, the implementation of low-dose methotrexate and other conventional disease-modifying anti-rheumatic drugs was introduced as an effective treatment. Second, it was recognized that early immunomodu- tory treatment is crucial for controlling the disease and its long-term destructive effects more effectively. Parallel advances in research on the pathogenesis of RA and cytokine biology converged in identifying tumor necrosis factor (TNF) as a key factor in inflammation and matrix destruction. The concept arose that elevated TNF concentrations at the sites of inflammation were driving disease pathology, and the removal of excess TNF from sites of inflammation became a therapeutic goal. Clearly, TNF blockade has revolutionized the treatment of RA, as well as other immune-mediated inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients |
| 出版日期 | Book 2009 |
| 关键词 | Arthritis; Chemokine; Drug Target; Interleukine; Rheumatology; antibody; cell; clinical trial; diseases; drug |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-7643-8238-4 |
| isbn_ebook | 978-3-7643-8238-4Series ISSN 1422-7746 Series E-ISSN 2296-4525 |
| issn_series | 1422-7746 |
| copyright | Birkhäuser Basel 2009 |
发表于 2025-3-21 20:01:04
